Four-Year Outcome of XEN 45 Gel Stent Implantation in a Swedish Population

Abstract

Purpose

To report the long-time success rate of XEN 45 gel stent implantation in a Scandinavian population.

Patients and Methods

This was a retrospective single-center analysis of all patients undergoing XEN 45 stent surgery between December 2015 and May 2017. The main outcome was success rate according to several definitions of success. Subgroup analysis was performed. Secondary outcomes were change in intraocular pressure (IOP) and number of IOP-lowering agents. Need for secondary glaucoma surgery, needling rate and complications were recorded.

Results

A total of 103 eyes could be evaluated after four years. Mean age was 70.6 years. Primary open-angle glaucoma (POAG) accounted for 46.6% and exfoliative glaucoma (PEXG) for 39.8%. Mean IOP dropped from 24.0 to 15.9 mmHg (p<0.001) and IOP-lowering agents from 3.5 to 1.5 (p<0.001). The success rate with individual target pressures after four years was 43.7%. Secondary glaucoma surgery was performed in 45 (43.7%) of cases. Combined cases (n=12) were not statistically different to stand-alone procedures (p=0.28). No difference between PEXG and POAG could be detected (p=0.44). During the learning curve, stent misplacement was common and resulted in worse outcome for less experienced surgeons.

Conclusion

The overall success rate of XEN 45 gel stent surgery in the present cohort is relatively low in a long-time follow-up under the given circumstances if all initial patients are included to follow-up. The influence of the surgeon’s learning curve is obvious, and improvement in success can be expected when used by experienced and high-volume surgeons. No significant differences were found in PEXG compared to POAG or in XEN surgery combined with cataract surgery compared to stand-alone.

Keywords:

• ab interno implant
• glaucoma
• minimal invasive glaucoma surgery
• pseudoexfoliative glaucoma
• surgical success
• XEN 45 gel stent

Introduction

Primary open-angle glaucoma is characterized by chronic progressive loss of the retinal nerve fiber layer and reduction of the optic nerve border, resulting in progressive reduction of the visual field. The risk for glaucoma rises with older age, heredity, elevated intraocular pressure (IOP), pseudoexfoliative syndrome (PEX), diabetes mellitus and ethnicity among other risk factors.¹

To inhibit progression of visual field loss, treatment consists mainly of lowering the IOP.² The hallmarks of glaucoma management are early detection and initiation of treatment as well as continuous compliance to medical treatment.

First-line treatment consists of topical IOP-lowering pharmacologic agents or selective laser trabeculoplasty (SLT).^3,4 Different substances have proven efficient and can be combined for additional IOP-lowering effect. In case of insufficient IOP control, intolerance due to side effects or suboptimal adherence to treatment, surgical intervention may become necessary.

Traditionally, the most frequent type of surgery has been filtering procedures (trabeculectomy, glaucoma shunts). Of these, trabeculectomy has been regarded as the gold standard procedure until recently.⁵ The complication profile of these procedures includes risk of infections, persistent hypotony, leakage, and fibrosis of the filtration bleb.⁶ Several new surgical techniques and devices have been introduced during the last years, often summarized as Minimal Invasive (or Incision) Glaucoma Surgery (MIGS), with the ambition for faster surgery, and better safety profile.⁷

The XEN 45 gel stent device (AbbVie Inc., North Chicago, IL, USA) consists of a 6 mm long gelatin tube with an internal diameter of 45 µm. It creates a new outflow facility for aqueous humor from the anterior chamber to the subconjunctival space.⁸ The mechanism of action is therefore comparable with trabeculectomy. As the device is implanted through a self-sealing limbal tunnel, neither conjunctival incision nor suturing is required, significantly shortening the surgery time compared to trabeculectomy.

The XEN gel stent is indicated for the management of refractory glaucoma as a stand-alone procedure or in combination with cataract surgery. In most studies, the type of procedure has no significant effect on the outcome,^9–11 while some studies found significantly more failures in combined cases in POAG.¹²

Long-time results with this relatively novel technique are still scarce. Published results in large cohorts are limited to three years at the best of our knowledge.^13,14 Furthermore, studies focusing on a Scandinavian cohort are lacking, which is of particular interest because of the high proportion of pseudoexfoliative glaucoma in this population.¹⁵ We consider it interesting to report the long-time results of our initial cohort, of which one-year results have been published earlier.¹⁶

Materials and Methods

Study Design

This was a single-center, retrospective observational chart review of all patients with open-angle-glaucoma who underwent glaucoma surgery with XEN 45 gel stent at the Department of Ophthalmology at Sahlgrenska University Hospital in Mölndal, Sweden between 1 December 2015 and 31 May 2017. The study protocol was approved by the local ethical committee before study initiation and was conducted in compliance with the declaration of Helsinki. The presented data was anonymized and due to the retrospective chart review, no written consent of the enrolled patients was regarded necessary by the ethical committee. For case presentation, written consent by the involved patient was obtained for publication, including photographs.

Study Population

All consecutive patients who underwent XEN 45 gel stent surgery alone (XEN stand-alone) or in combination with cataract surgery (combined XEN and cataract) during the study period were enrolled retrospectively. Patients were offered XEN 45 gel stent implantation if suitable as assessed by the surgeon. In our hands, the indication for XEN and trabeculectomy are virtually the same, as both methods have the same principal working mechanism. In cases with cataract and glaucoma, we prefer combined surgery with phacoemulsification and XEN stent instead of trabeculectomy. Indications for surgery were either uncontrolled intraocular pressure (IOP), intolerance to anti-glaucoma drugs, progression of visual field defects, or a combination of the factors mentioned above. There were no limitations concerning preoperative level of IOP, grade of visual field defect, or type of glaucoma. Eyes with previous filtrating glaucoma surgery including previous failed XEN surgery were excluded from analysis. In case of bilateral implantation, both eyes were included.

The data comprises the result of surgery performed by four anterior segment surgeons, none of whom had any previous experience of the XEN 45 gel stent.

Surgical Technique

The surgery was performed either as a stand-alone procedure or in combination with cataract surgery. Some patients received preservative-free dexamethasone a week prior to surgery, but most patients did not. Standard preoperative preparation was performed including local anesthesia with topical tetracaine (1%) (Tetracaine, Bausch&Lomb Nordic AB, Stockholm, Sweden). Preoperative miosis was achieved by topical pilocarpine 2% (Trimb Healthcare AB, Stockholm, Sweden) for stand-alone procedures. In the event of combined surgery, cataract surgery was performed first, after which mydriasis was converted to miosis by intracameral acetylcholine chloride, 10 mg/mL (Miochol-E^®, Bausch&Lomb Nordic AB, Stockholm, Sweden). In stand-alone procedures the anterior chamber was infused with xylocaine 10 mg/mL (Aspen Nordic, Ballerup, Denmark) and then filled with ocular viscoelastic device Healon GV (Johnson & Johnson Vision, Uppsala, Sweden). The conjunctiva in the upper nasal quadrant was hydrodissected by injection of 0.1 mL Mitomycin C 0.2 mg/mL or 5-Fluorouracil 50 mg/mL (extempore, Apoteket AB, Stockholm, Sweden). A peripheral corneal incision 1.2 mm wide was made nasally for later insertion of a counter-traction Vera hook (a1 medical GmbH, Radolfzell am Bodensee, Germany). The main incision of 1.8 mm width was placed as a peripheral corneal tunnel in the temporal inferior quadrant. The XEN^® 45 Gel Stent, preloaded into a XEN^® Injector (Allergan plc, Dublin, Ireland), was advanced through the anterior chamber, trabecular meshwork, and sclera. The XEN 45 gel stent was then released into the subconjunctival or subtenonal space. If unproperly positioned, further manipulations could be performed to optimize positioning, ie, explantation and reloading of the stent, or grasping the stent with forceps for manipulation of the stent through the intact conjunctiva. Intracameral Healon was removed and cefuroxime (Aprokam^® Laboratoires Théa, Clermont-Ferrand, France) was instilled in the anterior chamber at the end of the procedure.

Postoperatively, all topical and systemic (acetazolamide; Diamox^®, Amdipharm Ltd, London, Great Britain) anti-glaucomatous drugs were suspended, and anti-inflammatory topical therapy initiated with preservative-free dexamethasone 1 mg/mL (Dexafree^®, Laboratoires Théa, Clermont-Ferrand, France) 6–8 times/day. Depending on individual assessment, dexamethasone drops were tapered during a period of at least two months. Typically, follow-ups were scheduled at day 1 and after 1, 2, 3, 4, 6 and 8 weeks, with individual adjustments. In case of encapsulation or fibrosis, needling procedures were performed to cut adhesions between sclera and conjunctiva.

Baseline data included age at surgery, sex, type, and duration of glaucoma diagnosis, average IOP at the last three preoperative measurements, number of antiglaucoma agents, and dosage of oral acetazolamide. Postoperative IOPs at years 1, 2, 3 and 4 were retrieved from medical records. Adverse events and the need for interventions, ie, needling or secondary surgical interventions (SSI), were also noted. Needling of the failing filtration bleb could be used in cases with bleb fibrosis or tenon cysts as a rescue procedure. Needling was not considered as an SSI.

Outcomes and Definitions

Primary outcome was a clinical success rate, either complete or partial success. Complete success was defined as achieving target IOP four years after XEN implantation, without any medical treatment or SSI (ie, incisional surgery, laser treatments), while partial success was defined as reaching target IOP with pharmacologic IOP-lowering treatment but without SSI. Four levels of target-IOP were analyzed (Table 2). All other patients not meeting success-criteria were defined as failure. In addition, stents which were obviously non-functioning, ie, broken or without physical connection with the anterior chamber, were classified as failure. Secondary outcomes were changes in IOP and number of IOP lowering agents compared to baseline.

Statistical Analysis

All eyes with available medical charts were included in the analysis, but eyes which were classified as failure prior to the endpoint were considered as failure even when lost to follow-up. Mean ± standard deviation (SD) or proportions (%) are given. For outcome at four-year follow-up, Chi-square test or one-way analysis of variance (ANOVA) with Dunnett’s post hoc test were used. Survival plots based on Kaplan–Meier estimates were generated for cumulative survival (probability of clinical success) and Cox proportional hazard ratio was calculated. A p<0.05 was considered statistically significant. All statistics were performed on IBM SPSS Statistics for Macintosh, version 25.0 (IBM Corp, Armonk, NY, USA).

Results

During the study period, a total of 139 XEN 45 gel stents were implanted. Of these, 20 eyes were excluded from this study because of previous glaucoma surgery, resulting in a study cohort of 119 eyes. At the study endpoint at four years, 103 datasets were still available since 5 patients were deceased and 11 were lost to follow-up (Figure 1).

Figure 1 Flow chart describing study population. Deceased subjects and patients with missing data (n=10) were excluded from the one-year study population, resulting in a study population (N=103) with a four-year outcome.

At the time of surgery, the average age was 70.6 ±12.1 years. Gender was almost equally distributed. Most cases were either classified as primary open-angle glaucoma (46.6%) or pseudoexfoliative glaucoma (39.8%). Other types of glaucoma were rare, including secondary glaucoma after IOL-luxation, iridocyclitis, goniodysplastic glaucoma, previous angle closure glaucoma, venous stasis glaucoma and pigment dispersion glaucoma. The average duration of glaucoma, as defined from the time of diagnosis, prior to surgery was 9.2 years (Table 1). Mean preoperative IOP was 24.0 mmHg, ranging from 12.3 to 40.0 mmHg and the average number of pharmacologic IOP-lowering substances prior to surgery was 3.5 (range 0–6). At baseline, 54 eyes (52.4%) were pseudophakic. Antifibrotic agents were used in all cases. In 12 patients, both eyes were operated and included in the study. In 17 eyes, the target IOP was defined as lower than 20 mmHg (average 15 mmHg, range 12–18 mmHg). Overall, for the complete cohort, the average target IOP was 19.5 mmHg.

Table 1 Demographic Description for Study Population with Four-Year Outcome

Variable	N = 103
Age at surgery (years), mean ± SD	70.6 ±12.1
Sex, n (%)
Men	48 (46.6)
Women	55 (53.4)
Glaucoma type, n (%)
Primary open-angle	48 (46.6)
Pseudoexfoliative	41 (39.8)
Other^a	14 (13.6)
Duration of diagnosis (years), mean ± SD	9.2±8.1
Preoperative IOP (mmHg), mean ± SD	24.0±6.3
Pseudophakic, n (%)	54 (52.4)

Note: ^aIncluding secondary glaucoma after intraocular lens luxation, iridocyclitis, goniodysplastic glaucoma, previous angle closure glaucoma, venous stasis glaucoma, and pigment dispersion glaucoma.

Abbreviations: IOP, intraocular pressure; SD, standard deviation.

Surgical Outcomes

Of 103 surgeries, 12 were combined with cataract surgery, while 91 were performed as stand-alone procedures. A total of 14 patients were bilateral cases. Previous analysis showed no correlation between first and second eye outcome, leading to the decision not to exclude the second eye in our analysis.¹⁵

The overall success rate according to our individual IOP criteria was 43.7% (complete success 22.3%, partial success 21.4%). The success rate for different target IOP is shown in Table 2. The fastest decrease of success occurred during the first two months after surgery, as seen in a survival plot based on Kaplan–Meier estimates (Figure 2).

Table 2 Outcome with Different Intraocular Pressure (IOP) Targets

Target IOP	Complete Success n (%)^a,c	Partial Success n (%)^b,c	Failure n (%)
Individual target IOP^d	23 (22.3)	22 (21.4)	58 (56.3)
Individual target IOP^d AND ≥20% IOP reduction^e	19 (18.4)	19 (18.4)	65 (63.1)
15 mmHg target IOP	13 (12.6)	14 (13.6)	76 (73.8)
15 mmHg target IOP AND ≥20% IOP reduction^e	12 (11.7)	11 (10.7)	80 (77.7)
18 mmHg target IOP	16 (15.5)	22 (21.4)	65 (63.1)
18 mmHg target IOP AND ≥20% IOP reduction^e	14 (13.6)	16 (15.5)	73 (70.9)
21 mmHg target IOP	24 (23.3)	28 (27.2)	51 (49.5)
21 mmHg target IOP AND ≥20% IOP reduction^e	20 (19.4)	20 (19.4)	63 (61.2)

Notes: ^aComplete success was defined as achieved target IOP at four years without any medical treatment or secondary surgical interventions (ie, incisional surgery, laser treatments). ^bPartial success was defined as reaching target IOP at four years with pharmacologic IOP-lowering treatment but without secondary surgical interventions. ^cIn addition, for both complete and partial success less or equal number of IOP-lowering substances AND clinical undamaged, non-occluded stent was required. ^dIndividual IOP were as given in the medical charts, if not defined the target IOP was set to 20 mmHg. ^e20% reduction in IOP after four years compared to the preoperative IOP.

Abbreviation: IOP, intraocular pressure.

Figure 2 Survival plot based on Kaplan–Meier estimates showing four-year outcome of XEN implantation (N=103) and probability of clinical success, the remaining cases with complete success (target IOP attained without pharmacologic treatment) and partial success (target IOP attained with the aid of pharmacologic agents), a total of 45 cases (43.7%) after 48 postoperative months.

Accordingly, the failure rate was 56.3% (n=58). Of these, 45 cases (43.7%) have been subject for secondary glaucoma surgery at the study endpoint.

IOP reduction: In all eyes the mean IOP decreased from 24.0 mmHg at baseline to 16.0 mmHg (−33.3%), 15.1 mmHg (−37.1%), 15.1 mmHg (−37.1%) and 15.9 mmHg (−33.8%) at 1, 2, 3 and 4 years (p<0.001), respectively.

At the day of surgery, all medical glaucoma therapy was cancelled. For some patients, anti-glaucoma medication had to be reintroduced during the study period (Figure 3). Forty-five eyes underwent additional IOP-lowering procedures. The average number of substances was significantly reduced from 3.5 preoperatively to 1.5 at 4 years postoperatively, p<0.001 (ANOVA with Dunnett’s post hoc). Before surgery, 36 cases were treated with oral acetazolamide, at four-year follow-up, no patient was in need for this medication.

Figure 3 Pharmacologic treatment of glaucoma patients subjected to XEN implantation, showing mean number of topical substances and mean intraocular pressure (IOP) preoperatively and after four postoperative years. All XEN-patients in the cohort (N=103) were included initially and patients with secondary glaucoma surgery were excluded at the time of the secondary surgery.

Type of Glaucoma

Cases with pseudoexfoliative glaucoma (PEX) showed an initial trend towards higher failure rates compared to simplex glaucoma (Figure 4), but this difference diminished over time and there was no significant detectable difference between these groups at the study endpoint (p=0.44).

Figure 4 Survival plot based on Kaplan–Meier estimates for XEN implantation with different types of glaucoma; primary open-angle glaucoma (n=48) and pseudoexfoliative glaucoma (n=41). The probability of clinical success was 43.8% and 43.9% respectively after 48 months follow-up. Cox proportional hazard ratio=0.89 (95% CI=0.51–1.55), p=0.68.

Combined versus Stand-Alone Surgery

One year after surgery, combined cases seemed to have a more favorable outcome compared to stand-alone surgery (Figure 5), but this initial trend faded over time and there was no significant difference between the two groups at study endpoint (p=0.28).

Figure 5 Survival plot based on Kaplan–Meier estimates for XEN gel stent procedure when combining XEN and cataract, with phacoemulsification and intraocular lens implantation (n=12), and for XEN stand-alone (n=91). Probability of clinical success was 50.0% and 42.9% respectively after 48 months follow-up. Cox proportional hazard ratio=1.38 (95% CI=0.59–3.20), p=0.46.

Surgeon’s Impact

The outcome for the four surgeons involved in this study differed significantly (Table 3). The most productive surgeon had a clinical success rate of 55.7% (N=61) at four years, compared to 37.5% (N=16), 16.7% (N=18) and 25.0% (N=8), respectively, for lower-volume surgeons (Figure 6).

Table 3 Stent misplacement and Final Failure Rates

Surgeon	Number of Surgeries	Curved Stent (%)	Malpositioned Stent (%)	Final Failure (%)
#1	16	6.3	25	62.5
#2	61	9.8	16	44.3
#3	18	11.1	22	83.3
#4	8	12.5	25	75.0

Figure 6 Survival plot based on Kaplan–Meier estimates for XEN gel stent procedures for different surgeons (A–D). Probability of clinical success was 37.5% for surgeon A (N=16), 55.7% for surgeon B (N=61), 16.7% for surgeon C (N=18) and 25.0% for surgeon D (N=8), after 48 months follow-up.

Second Eye Surgery

In 14 cases second eye surgery occurred. No statistical difference in outcome between first and second eye surgery was observed, failure rate was 54% in total (50% for first eye surgery, 57% for second eye surgery).

Complications

Misplacement

Of 103 stents, 73 (70.9%) were judged to be perfectly implanted with straight extraocular appearance and correct placement in relation to anterior chamber anatomy and length inside/outside the eye. Ten stents (9.7%) were seen with curved extraocular appearance indicating incarceration in subconjunctival tissues. Of these, 7 (70%) had failed at the study endpoint, 2 (20%) had partial success and one converted to complete success after intensive needling on five occasions.

A total of 20 stents (19.4%) were incorrectly implanted. Of these, 13 were entrapped in iris tissue, 3 too short externally, 3 too long externally (no contact with anterior chamber) and one stent was judged being in contact with endothelium (later explanted). Of these 20 stents, 16 (80%) had failed at the study endpoint (of these, 14 had secondary glaucoma surgery), three stents fulfilled the criteria for partial success and one for complete success (entrapped iris which resolved after YAG iridotomy).

Other Complications

The most common complications were temporary hypotony on the first postoperative day with IOP below 7 mmHg (n=16); persistent hypotony <7 mmHg was not observed, shallow anterior chamber (n=11) (iridocorneal contact was not observed) and choroidal detachment (n=14). Smaller hyphemas were often evident on day one postoperatively (n=18). Prolonged bleeding for more than one week was rare (n=2). All hyphemas resolved without surgical intervention. Other complications occurred seldomly (Table 4). No endophthalmitis or blebitis was observed. Only a few complications occurred after the first year: in two patients the visual field was completely lost, both patients had undergone secondary glaucoma surgery at that time. One late migration of XEN stent was observed, see case presentation below and Figure 7A–C. One surgical revision was necessary because of avascular conjunctiva. Surgical revision of encapsulated blebs was performed instead of needling in four cases, all of these were automatically classified as failure (secondary surgical intervention) regardless of outcome. In one of these cases, the XEN stent was accidentally damaged by surgical manipulation, and surgery converted to trabeculectomy in the same session. Late needling was performed in two cases, one leading to complete success, the other one a failure due to later cyclodiode laser treatment.

Table 4 Complication Rates

Complication	Incidence n (%)
Iris incarceration	13
Cataract surgery due to iris incarceration	4
Stent misplacement anteriorly (endothelial contact):	1
Stent misplacement exteriorly (too long exteriorly)	3
Stent misplacement interiorly (too long in anterior chamber)	3
Stent misplacement: curved exterior	10
Shallow anterior chamber	11 (1 OVD fill-up, 1 YAG iridotomy)
Fibrin and corneal oedema day 1	1
Hypotony day 1 (IOP <7 mmHg)	16
Hypertony day 1 (IOP >30 mmHg)	4
Choroidal detachment	14
Hyphema day 1	18
Hyphema >1 week	2
Epithelial defect	1
Migration of stent	1
Conjunctival leakage/avascularity requiring surgical revision	1
Needling (<1 year)	44
Late needling (>1 year)	2

Abbreviation: IOP, intraocular pressure.

Figure 7 (A) January 2016: functioning but curved XEN 45 gel stent in place. IOP 18 mmHg without treatment 15 days after surgery. (B) March 2018 prior to needling. Pigment in XEN stent lumen, no effusion, IOP 21 mmHg on brinzolamide/brimonidine tartrate (Simbrinza^®), bimatoprost (Lumigan^®) and betaxolol (Betoptic^®). The stent has migrated out of the anterior chamber and has no visible connection with aqueous humor on gonioscopy. (C) March 2018 post needling. The Xen stent lumen has been massaged through the intact conjunctiva towards the anterior chamber and the stent lumen is visible again on gonioscopy. Needling under and above the outer stent ostium has been performed straightening the stent, with no initial effect om filtration. The utmost part of the stent with pigmented embolus has thereafter been cut by needling (arrow), pigment and aqueous humor have drained to the subconjunctival space forming an ordinary filtration bleb (asterisk). IOP after one week washout of antihypertensive drugs = 12 mmHg.

Case Presentation

One exceptional case demonstrates the potential of late needling even after several years: We would like to present the case of a female patient with bending of the functioning stent (Figure 7A). The inner stent lumen had been implanted adjacent to the iris surface, but its inner lumen was free as observed by gonioscopy, and filtration was observed, although the outer portion of the stent was bend. Three months after surgery, the stent migrated outside the anterior chamber, and a thin layer of iris tissue was observed overlying the inner stent lumen. IOP raised, which was treated with several IOP-lowering agents. Two years after surgery, occlusion of the entire stent lumen with agglomerated pigmented material and absence of filtration was documented (Figure 7B). In the meantime, the patient had even undergone cataract surgery. By manipulation in the slit lamp, the stent could be re-located some millimeter towards the anterior chamber two years after implantation, while the stent was straightened, and filtration restored by needling (Figure 7C). During the following year, the IOP was well controlled without medication. One year later, renewed stent migration towards the sclera led to complete failure (disconnection between inner stent lumen and anterior chamber).

Discussion

The basic surgical XEN stent implantation technique is relatively easy to learn for an experienced anterior segment surgeon. However, our data indicate that surgeons with higher volumes are more likely to achieve better results than low-volume surgeons. In our cohort, results between different surgeons varied significantly. We believe that this is not due to follow-up management, because most patients were treated by a variety of different surgeons after surgery. Aspects that may influence the surgical outcome are technique and choice of antimetabolite injection, positioning of the stent in relation to chamber angle structures and iris, adjustments of stent position under Tenons capsule and conjunctiva and primary needling of subconjunctival adhesions around the stent. Our study was not designed to determine which of these above-mentioned aspects that may play a crucial role for the outcome. Nevertheless, the high proportion of incorrectly positioned (n=20) and curved stents (n=10) indicate that high precision in stent positioning is crucial. The surgeon with the lowest rate of malpositioning also had the lowest rate of failure.

Some aspects of malpositioning were not yet known by the time of introduction of the XEN gel stent: curved stents can show normal filtration behavior during surgery and the first weeks after surgery. Primary needling, which is now the technique of choice to achieve a straight and freely mobile stent,¹⁷ was not launched in the beginning of this study. Even obliterated stents by iris incarceration can initially present with functioning filtration blebs by side-flow through the intrascleral implantation channel.

Short-Time Failure

Our survival plot demonstrates a rapid decline in function during the first weeks after surgery. We interpret this as being the result of partly insufficient implantation technique during the learning curve, as several implanted stents never came into proper function due to for instance stent damage or improper implantation, ie, iris incarceration. In our previous study, we were able to show that the initial 30 patients during the learning curve had a three times higher failure rate at one year post surgery than the following 30 patients by the same surgeon, indicating large improvement potential by experience.¹⁶

Long-Time Failure

Scar-formation and fibrosis are unlikely to occur during the first two weeks after surgery but are the main reason for declining success rate in the long term. Needling of fibrosis or Tenon cysts around the XEN gel stent ostium can resolve malfunction. In our cohort, 44 eyes (42%) underwent at least one needling procedure during the first six months after surgery. This is in line with other published cohorts; 43.0%, 36.6%, and 55.4%.^12,18,19 Thereafter, needling was seldomly performed. In some cases, function of the stent could nevertheless be re-established a long time after surgery. Five cases were identified obtaining needling >12 months after surgery. Of these, two were converted from failure to complete success, two from partial success to complete success and one failed at the study endpoint.

In the systematic review of Chen et al, eight publications with 36 months of follow-up were identified, three of these with cohorts of more than 50 surgeries.¹⁴ Table 5 gives an overview over these together with our own data.

Table 5 Comparison of Our Data at Four Years and Some of the Largest Studies with at Least Three Years of Follow-Up

Author	Initial Population (n)	IOP Preop (mmHg)	Medication Preop (n)	Population at Endpoint (n)	IOP Postop 3 Years (mmHg)	Medication Postop (n)	Failure Rate (%)	Needling Rate (%)	Secondary Surgical Intervention (%)
Gabbay et al^Citation10	205	22.6	2.6	53	14.0	0.6	25	36.6	17.1
Reitsamer et al^Citation9	174	20.7	2.7	85	13.9	1.1	32	43	12.3
Gillman et al^Citation12	149	20.8	1.9	92	13.1	0.4	40	55.4	26.1
Busch et al*	103	24.0	3.5	103	15.1	1.5	56.3	42	43.7

Note: *The current study, presenting 4-year outcome.

Abbreviation: IOP, intraocular pressure.

In comparison with these long-term publications, our population presented with a higher level of IOP and more extensive medication at baseline. This indicates differences in study populations (more advanced stage of glaucoma) and later surgical intervention in our study. The Scandinavian population is characterized by a high proportion of pseudoexfoliative glaucoma. In our cohort, PEX accounted for 39.8% of all cases, compared to 11.8%.⁹ However, our study could not detect any significant difference between PEX and primary open-angle glaucoma at the study endpoint. This is in line with most published results as summarized by Fea et al.²⁰

A strength of the present study is that we report the results of a complete cohort over the duration of four years, while comparable studies have a significant reduction in number of cases over time (3-year-drop-out 52.4%⁹ and 74.1%¹⁰ respectively). Most researchers exclude failed cases after secondary glaucoma surgery, so that the results of the remaining study population appear to be more successful than the initial cohort. In short-term studies in which no patient is excluded from follow-up, the failure rate at 12 months can be as high as 51.4% in a population with difficult cases, with 60% previous incisional glaucoma surgery,²¹ which seems to be a realistic real-world result. To ensure the most comprehensive follow-up, cases with early failure were enclosed in the outcome, even if the patients later were lost to follow-up, thus leading to an overrepresentation of negative events.

A limitation of the present study is the retrospective study design. Follow-up was performed by multiple clinics, and the postoperative treatment was not standardized. No definition of success was established before surgery, thus leading to different interpretation of outcome and management of the patient’s medication. Some IOP-lowering effect may be caused by cataract surgery in combined cases. Caution should be taken with subgroup analysis, since it may lead to small subgroups with compromise of statistical power.

The present results are reported according to internationally recommended standards, although the criteria are not perfectly suited for a retrospective study approach. It is impossible to isolate the IOP-lowering effect of the XEN gel stent expressed in percentage as we compare preoperatively heavily treated IOP with post-surgery IOP under a significantly reduced medication. Thus, the demand of at least 20% IOP reduction can be too strict under certain circumstances. Some authors therefore extend the definition of success to include even cases with reduction of antihypertensive medication without an increase in baseline IOP.¹⁰

Conclusions

In summary, the present study demonstrates that XEN gel stent surgery is a safe small-incision-procedure which has the potential to lower IOP substantially. Patients should be informed about the potential need for postsurgical needling, medication and/or secondary surgical interventions to achieve target IOP. Only a minority of patients reach low IOP (<15 mmHg).

The majority of drop-out occurs during the first months after surgery and might be due to suboptimal placement of the stent. Outcomes can be maximized by correct placement of the stent both in relation to anterior chamber structures and subconjunctivally (primary needling). We recommend performing XEN stent surgery in a specialized glaucoma clinic with high volumes.

Disclosure

TB and AB have received lecture fees and travel expenses from AbbVie. The authors report no other conflicts of interest in this work.

Additional information

Funding

The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF-GBG-725041), Göteborg Medical Society, Dr Reinhard Marcuses Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjalmar Svensson Foundation, Greta Andersson Foundation, Agneta Prytz-Folkes och Gösta Folkes stiftelse, De Blindas Vänner and Kronprinsessan Margaretas Arbetsnämnd för Synskadade.